Genetic protein TmSm(T34A) enhances sensitivity of chemotherapy to breast cancer cell lines as a synergistic drug to doxorubicin

Biomedicine and Pharmacotherapy

Volumn 66, Issue 5, 2012, Pages 368-372

  Xu, Yuxin ^a   Zheng, Wenyun ^a   Wang, Tianwen ^b   Wang, Ping ^a   Zhu, Ling ^a   Ma, Xingyuan ^a  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b JIANGNAN UNIVERSITY   (China)

Author keywords

Breast cell lines; Chemotherapeutic agent; Enhancing sensitivity; Genetic protein TmSm(T34A)

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; GENETIC PROTEIN TMSM; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL STRAIN MCF 7; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SENSITIZATION;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BREAST NEOPLASMS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; RECOMBINANT FUSION PROTEINS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84864021256     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2011.12.004     Document Type: Article

References (33)

1. Zaffaroni N., et al. Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci 2002, 59:1406-1412.
2. Longley D.B., Johnston P.G. Molecular mechanisms of drug resistance. J Pathol 2005, 205:275-292.
3. Adamkov M., Halasova E., Kajo K., Machalekova K., Vybohova D., Varga I., et al. Survivin: a promising biomarker in breast carcinoma. Neoplasma 2010, 57:572-577.
4. Giménez-Bonafé P.T.A., Pérez-Tomás R. Overcoming drug resistance by enhancing apoptosis of tumor cells. Curr Cancer Drug Targets 2009, 9:320-340.
5. Di Stefano A.B., Iovino F., Lombardo Y., Eterno V., Hoger T., Dieli F., et al. Survivin is regulated by interleukin-4 in colon cancer stem cells. J Cell Physiol 2010, 225:555-561.
6. Gan X.L., Li J.K., Yu T.H., Zhang Y., Hu L.N. High expressions of bcl-2 and survivin, and decreased apoptosis in uterine cervical carcinosarcoma compared to cervical squamous cell carcinoma. Arch Gynecol Obstet 2010, 284:175-181.
7. Altieri D.C. The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol 2006, 18:609-615.
8. Morgillo F., Woo J.K., Kim E.S., Hong W.K., Lee H.Y. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 2006, 66:10100-10111.
9. Tran J., Master Z., Yu J.L., Rak J., Dumont D.J., Kerbel R.S. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci U S A 2002, 99:4349-4354.
10. Lens S.M., Vader G., Medema R.H. The case for Survivin as mitotic regulator. Curr Opin Cell Biol 2006, 18:616-622.
11. Li F., Brattain M.G. Role of the Survivin gene in pathophysiology. Am J Pathol 2006, 169:1-11.
12. Ma X.Y., Zheng W.Y., Wei D.Z., Ma Y.S., Wang T.W., Wang J.Z., et al. High-level expression, purification and pro-apoptosis activity of HIV-TAT-survivin (T34A) mutant to cancer cells in vitro. J Biotechnol 2006, 123:367-378.
13. Zhang H., Zheng Y., Liu Q., Tao X., Zheng W., Ma X., et al. Development of a fed-batch process for the production of anticancer drug TATm-survivin(T34A) in Escherichia coli. Biochem Eng J 2009, 43:163-168.
14. Shapiro G.I. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin Cancer Res 2004, 10:4270s-4275s.
15. Pennati M., Colella G., Folini M., Citti L., Daidone M.G., Zaffaroni N. Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. J Clin Invest 2002, 109:285-286.
16. Pennati M., De Cesare M., Pratesi G., Folini M. Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo. Carcinogenesis 2004, 25:1129-1136.
17. Chao J.I., Su W.C., Liu H.F. Baicalein induces cancer cell death and proliferation retardation by the inhibition of CDC2 kinase and survivin associated with opposite role of p38 mitogen-activated protein kinase and AKT. Mol Cancer Ther 2007, 6:3039-3048.
18. Azuhata T., Scott D., Griffith T.S., Miller M., Sandler A.D. Survivin inhibits apoptosis induced by TRAIL, and the ratio between survivin and TRAIL receptors is predictive of recurrent disease in neurobtastoma. J Pediatr Surg 2006, 41:1431-1440.
19. Kojima H., Iida M., Yaguchi Y., Suzuki R., Hayashi N., Moriyama H., et al. Enhancement of Cisplatin sensitivity in squamous cell carcinoma of the head and neck transfected with a survivin antisense gene. Arch Otolaryngol Head Neck Surg 2006, 132:682-685.
20. Sharma H., SS, Lo Muzio L., Mariggiò A., Singh N. Antisense-mediated downregulation of anti-apoptotic proteins induces apoptosis and sensitizes head and neck squamous cell carcinoma cells to chemotherapy. Cancer Biol Ther 2005, 4(7):720-727. [Epub 2005 Jul 2].
21. Kim K.W., et al. Inhibition of survivin and aurora B kinase sensitizes mesothelioma cells by enhancing mitotic arrests. Int J Radiat Oncol Biol Phys 2007, 67:1519-1525.
22. Dean E.J., Ranson M., Blackhall F., Holt S.V., Dive C. Novel therapeutic targets in lung cancer: inhibitor of apoptosis proteins from laboratory to clinic. Cancer Treat Rev 2007, 33:203-212.
23. Nakagawa Y., et al. IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes. Am J Hematol 2006, 81:824-831.
24. Rodel F., Hoffmann J., Distel L., Herrmann M., Noisternig T., Papadopoulos T., et al. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 2005, 65:4881-4887.
25. Dohi T., Beltrami E., Wall N.R., Plescia J., Altieri D.C. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 2004, 114:1117-1127.
26. Marusawa H., Matsuzawa S.I., Welsh K., Zou H., Armstrong R., Tamm I., et al. HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J 2003, 22:2729-2740.
27. Shiu L.Y., Liang C.H., Huang Y.S., Sheu H.M., Kuo K.W. Solamargine induces apoptosis and sensitizes breast cancer cells to cisplatin. Food Chem Toxicol 2007, 45:2155-2164.
28. Piro L.D Apoptosis, Bcl-2 antisense, and cancer therapy. Oncology (Williston Park) 2004, 18:5-10.
29. Buchele T. Proapoptotic therapy with oblimersen (bcl-2 antisense oligonucleotide)--review of preclinical and clinical results. Onkologie 2003, 26(Suppl. 7):60-69.
30. Altieri D.C. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008, 8:61-70.
31. Son B.H., Ahn S.H., Ko C.D., Ka I.W., Gong G.Y., Kim J.C. Significance of mismatch repair protein expression in the chemotherapeutic response of sporadic invasive ductal carcinoma of the breast. Breast J 2004, 10:20-26.
32. Osanai M., Murata M., Chiba H., Kojima T., Sawada N. Epigenetic silencing of claudin-6 promotes anchorage-independent growth of breast carcinoma cells. Cancer Sci 2007, 98:1557-1562.
33. Mesri M., Wall N.R., Li J., Kim R.W., Altieri D.C. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest 2001, 108:981-990.